Evidence map›Paper›PMID 41122230›Full record

ArticleMaterials today. Bio2025

Biomimetic polymersomal nanoreactors for hepatocyte-directed detoxification in drug-induced liver injury.

Wenxing Gu, Ruxue Bai, Jiaxin Wang, Jun Wang, Chongzhou Fang, Yuanchao Shi, Peixing Wang, Qiaoqiao Wang, Wei Bing, Tian Xie and 1 more

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenxing GuInstitute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Ruxue BaiInstitute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Jiaxin WangInstitute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Jun WangInstitute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Chongzhou FangInstitute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Yuanchao ShiInstitute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Peixing WangSchool of Pharmacy, Zhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
Qiaoqiao WangSchool of Pharmacy, Zhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
Wei BingSchool of Chemistry and Life Science, Changchun University of Technology, Changchun, 130012, China.
Tian XieSchool of Pharmacy, Zhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
Jing MuInstitute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury (DILI) is a major clinical concern associated with drug toxicity, primarily characterized by hepatocyte damage driven by oxidative stress and inflammation. Excessive accumulation of reactive oxygen species (ROS) and pro-inflammatory cytokines exacerbates liver injury, necessitating effective therapeutic interventions. While natural antioxidant enzymes exhibit high catalytic activity and specificity in ROS scavenging, their clinical use is limited by poor stability in circulation and limited cellular uptake. To address these challenges, we developed antioxidant polymersomal nanoreactors (CS@PS) for the targeted co-delivery of catalase (CAT) and superoxide dismutase (SOD). CS@PS functions as a cascade system, efficiently neutralizing ROS and mitigating inflammation in hepatocytes. Notably, systemic administration of CS@PS exhibits targeted delivery to hepatocytes, ensuring enzyme stability and bioavailability. In a model of acetaminophen-induced liver injury, CS@PS significantly reduced hepatic ROS levels and alleviated liver damage, underscoring its therapeutic potential. This study highlights the promise of CS@PS as an innovative antioxidant nanoreactor for DILI treatment offer a promising strategy for managing other ROS-mediated diseases.

Indexed as

Drug-induced liver injuryHepatocyte targetingNanoreactorPolymersomeReactive oxygen species

Identifiers

PMID41122230
PMCPMC12536553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.